AI-generated summary
The authors report a polydopamine nanoplatform loaded with the drug JQ1, which lowers PD-L1 expression and inhibits c-MYC in triple-negative breast cancer models, combined with photothermal therapy. The combination was associated with activation of cytotoxic T lymphocytes and an immune-memory effect protecting mice from tumor re-challenge. The study appears to be preclinical, with findings limited to laboratory and mouse experiments.
- Who or what was studied
- Triple-negative breast cancer models in mice and cells
- Limits stated in the abstract
- The abstract does not report human participants, so findings come from preclinical mouse and cell work and may not transfer to patients.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on pubs.acs.org.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.